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Abstract 
This randomized trial compared the sequential use of letrozole and gonadotrophin (HMG) with 
HMG only in poor ovarian responders undergoing IVF. Patients with < four oocytes retrieved in 
previous IVF cycles or < 5 antral follicles were randomized to either letrozole for 5 days 
followed by HMG or HMG alone. 53 women were recruited. The letrozole group had 
significantly lower dosage of HMG (P < 0.001), shorter duration of HMG (P < 0.001) and fewer 
oocytes (P = 0.001) when compared to the control group. Live-birth rate was comparable with a 
significantly lower miscarriage rate in the letrozole group ((P = 0.038). Serum FSH 
concentrations were comparable in both groups except on Day 8, while estradiol concentrations 
were all significantly lower in the letrozole group from day 4. Follicular fluid concentrations of 
testosterone, androstenedione, FSH and AMH were significantly higher in the letrozole group (P 
= 0.009, P = 0.001, P = 0.046 and P =0.034 respectively). When compared to HMG alone, 
sequential use of letrozole and HMG in poor responders resulted in significantly lower total 
dosage and shorter duration of HMG, a comparable live-birth rate, a significantly lower 
miscarriage rate but a more favourable hormonal environment of follicular fluid. 
Keywords: follicular fluid; in-vitro fertilization; letrozole; live-birth rate; poor ovarian 
responders  
  3 
Introduction 
 
In vitro fertilization (IVF) is an effective treatment for various causes of subfertility. It involves 
ovarian stimulation for multiple follicular development, oocyte retrieval and embryo transfer 
after fertilization. Multiple embryos are usually transferred to compensate for their low 
implantation potential, which has remained steady at 20-25%, despite recent advances in ovarian 
stimulation, gamete handling, assisted fertilization and embryo culture. The success of embryo 
cryopreservation also makes it desirable to obtain multiple embryos to allow an increased 
number of embryo transfers, thus increasing the cumulative pregnancy rates (Wang et al. 1994).  
 
Therefore, the development of multiple follicles in response to gonadotrophin stimulation is 
usually considered as one of the key factors leading to a successful outcome. Poor ovarian 
response has usually been associated with low pregnancy rates and many of these cycles are 
cancelled without proceeding to oocyte retrieval (Keay et al. 1997). The management of poor 
ovarian responders has been extensively reviewed (Keay et al. 1997; Karande and Gleicher 1999; 
Fasouliotis et al. 2000; Surrey and Schoolcraft 2000; Mahutte and Arici 2002; Tarlatzis et al. 
2003) but remains a great challenge in assisted reproduction technology.  
 
Letrozole, a third-generation reversible aromatase inhibitor, has been tried in poor responders 
undergoing IVF treatment. It inhibits the aromatization of androgen into estrogen, which in turn 
reduces the negative feedback resulting in an increase in gonadotrophins, that is the underlying 
mechanism of its use in ovulation induction (Mitwally and Casper 2001). The sequential use of 
letrozole and gonadotrophins was reported to induce more mature follicles in intrauterine 
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insemination cycles (Mitwally and Casper 2002). A few studies (Goswami et al. 2004; Garcia-
Velasco et al. 2005; Verpoest et al. 2006; Schoolcraft et al. 2008; Ozmen et al. 2009; Yarali et al. 
2009; Davar et al. 2010) on the use of letrozole in poor ovarian responders undergoing IVF 
treatment have been reported but their results are not consistent.  
 
We conducted this randomized trial to compare the sequential use of letrozole and gonadotrophin 
with gonadotrophin only in poor ovarian responders or women with poor ovarian reserve 
undergoing IVF treatment.   
 
Materials and Methods 
Study population 
Subfertile patients attending Centre of Assisted Reproduction and Embryology The University of 
Hong Kong - Queen Mary Hospital were recruited if they had less than four oocytes retrieved in 
their previous failed IVF cycles or were found to have less than five antral follicles as assessed 
during early follicular phase within two months preceding the IVF treatment cycle. Those aged 
above 40 or having major medical illness such as severe hepatic or renal impairments were 
excluded.  
 
Consecutive women who fulfilled the selection criteria and were willing to participate were 
counseled and recruited. They gave an informed written consent prior to participating in the 
study, which was approved by the Institutional Review Board of the University of Hong 
Kong/Hospital Authority Hong Kong West Cluster. The trial was registered on the 
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HKClinicalTrials.com with the trial number HKCTR-1158. Subjects were recruited to join the 
study only once and did not receive any monetary compensation for participation in the study.  
  
Randomization and treatment regimen 
Eligible women were recruited on the second day of the treatment cycle and underwent an 
ultrasound scan to exclude the presence of ovarian cysts. They were then randomized according 
to a computer-generated randomization list in sealed, opaque envelopes into two groups: the 
letrozole and control groups. The sequence of allocation was concealed until interventions were 
assigned by the research nurse after the patients were recruited by an investigator. In the 
letrozole group, women received letrozole (Femara; Norvatis, East Hanover, NJ, USA) 2.5 mg 
daily from day 2 to day 6 for 5 days. This was followed by a fixed daily dose of intramuscular 
injection of 225 IU human menopausal gonadotrophin (HMG, Menogon, Ferring GmbH, Kiel, 
Germany) until the day of human chorionic gonadotrophin (hCG) administration. In the control 
group, they were given a fixed daily dose of 225 IU HMG from day 3 onwards. Ovarian 
response was monitored by serial transvaginal scanning and hormonal assays from day 6 
onwards. Ganirelix 0.25mg (Orgalutran®, Organon) was administered when the leading follicle 
was ≥ 12mm in diameter. Human chorionic gonadotrophin (hCG) at a dose of 10000 IU (Profasi, 
Serono, Geneva, Switzerland) was given if at least one follicle was ≥ 18 mm in diameter. Oocyte 
retrieval was scheduled 36 hours after the hCG injection. 
 
Oocyte retrieval was performed using a 16 gauge double-channel needle (Cook IVF, Cook, 
Australia) under ultrasound guidance with a 5 MHz vaginal probe fitted with a needle guide. The 
double-channelled needle allowed aspiration and flushing of follicles >10 mm from both ovaries. 
Follicular fluid of the first mature follicle on both sides not contaminated with blood was 
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collected for hormonal analysis using medium-free collection tubes. Each follicle was flushed 
once with culture media and the fluid obtained from the aspiration and flushing was examined by 
an embryologist. The retrieved oocytes were inseminated conventionally or by intracytoplasmic 
sperm injection (ICSI) as indicated. Fertilization was checked 14-18 hours after the insemination. 
An oocyte was considered to be normally fertilized when two pronuclei were visible. When no 
pronucleus or only one pronucleus was visible, the oocyte was cultured for another 3-4 hours and 
examined again. A maximum of two normally cleaving embryos were transferred to the uterine 
cavity two days after the retrieval.  
 
Blood was taken for determination of serum estradiol (E2), progesterone (P), follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) concentrations on alternate days from day 2 until 
the day of oocyte retrieval (hCG+2). Serum E2 and P concentrations were checked on hCG+10 
day. Follicular fluid was assayed for E2, P4, FSH, LH, anti-Müllerian hormone (AMH), total 
testosterone, androstenedione and inhibin B concentrations. The sensitivity, intra-assay and inter-
assay coefficients of variation for hormonal assays were summarized in Table 1. Urine 
pregnancy test was performed 20 days after the ovulatory dose of hCG.  
 
Ongoing pregnancies were those pregnancies beyond 10-12 weeks of gestation, at which stage 
the patients were referred out for antenatal care. Live-birth was defined as the delivery of live-
birth after 24 gestational weeks. 
 
Outcome measures 
The primary outcome measure of the study was the number of oocytes retrieved. The secondary 
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outcome measures were serum and follicular fluid hormone concentrations, ongoing pregnancy 
rate, live-birth rate, cumulative live-birth rate including the live-births resulting from the transfer 
of frozen-thawed embryos, and total dosage and duration of stimulation with gonadotrophins.   
 
Statistical analysis 
We had shown previously that when the AFC was less than 5, the mean number of oocytes 
retrieved was 4.3 (Ng et al. 2000). Co-administration of letrozole improved the ovarian response 
from a mean number of follicles from 1.9 to 3.3 (Mitwally and Casper 2002). If the same 
improvement can be assumed for the number of oocytes, then co-administration of letrozole will 
increase the mean number of oocytes in our patients from 4.3 to 7.5. In order to detect such a 
difference with a power of 80% at 5% significance level, 33 patients would be needed in each 
group. We aimed to recruit 35 patients in each group to allow for patients who might dropout 
after recruitment. 
 
The Kolmogorov-Smirnov test was used to test the normal distribution of continuous variables. 
Results of continuous variables were given as mean ± standard deviation (SD) if normally 
distributed, and as median (range) if not normally distributed. Statistical comparison was carried 
out by Student’s T test, Mann-Whitney U-test, Wilcoxon signed ranks test for continuous 
variables and chi-squared test or Fisher’s Exact Test for categorical variables, where appropriate. 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS Inc., 
Version 17.0, Chicago, USA). The two-tailed value of P <0.05 was considered statistically 
significant.  
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Results 
Study population 
During the study period between 1st September 2005 and 30th September 2009, 65 consecutive 
eligible patients were approached and 53 patients were recruited. The study was prematurely 
terminated before reaching the pre-defined sample size due to recruitment difficulties. Twenty-
six subjects were randomized to the letrozole group while 27 subjects were in the control group. 
(Figure 1). There was no adverse event in both groups leading to cessation of treatment cycles.  
 
The demographic data were shown in Table 2. There were no significant differences in age of 
women, duration of subfertility, body mass index, the percentage of primary subfertility, the 
cause of subfertility and the smoking status between the letrozole and control groups. 
 
Outcomes 
The letrozole group used a significantly lower dose of HMG and had a significantly shorter 
duration of HMG when compared with the control group (Table 3). The duration of GnRH 
antagonist was comparable in both groups. The number of oocytes retrieved was significantly 
lower in the letrozole group than that in the control group (P = 0.001) but the number of embryos 
transferred was similar for the two groups. The cancellation rate, implantation rate, ongoing 
pregnancy rate, live-birth rate and cumulative live-birth rate (23.1% (6/26) vs 7.4% (2/27), p 
0.111) were comparable for both groups. A significantly lower miscarriage rate was noted in the 
letrozole group than the control group (0% vs 60%, respectively, p=0.038). 
 
Serum and follicular fluid hormonal profiles 
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Serum E2 concentration of the letrozole group was significantly lower than that of the control 
group from Day 4 to the day of hCG administration. FSH concentrations of the letrozole and 
control groups were comparable on most of the days, except on day 8 when the FSH 
concentration of the letrozole group was significantly lower than that of the control group. Serum 
LH concentration was significantly higher in the letrozole group than that in the control group 
from Day 4 to D8. (Figure 2) 
 
Follicular fluids were collected in 36 patients (18 in the letrozole group and 18 in the control 
group). Follicular FSH, testosterone, androstenedione and AMH concentrations were 
significantly higher in the letrozole group than those in the control group (P = 0.046, P = 0.009, 
P = 0.001 and P =0.034 respectively; Table 4). Other hormones were similar between the two 
groups.  
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Discussion 
 
Results of this randomized study confirmed that sequential use of letrozole and HMG in poor 
ovarian responders significantly reduced the total dosage and duration of HMG used. Although 
the number of oocytes retrieved was significantly lower in the letrozole group, the live-birth rate 
was similar for both groups. It was also shown that serum FSH concentrations were comparable 
in both groups on the majority of the days during ovarian stimulation. Follicular fluid 
concentrations of testosterone, androstenedione, FSH and AMH were significantly higher in the 
letrozole group. 
 
The management of poor ovarian responders remains a great challenge in assisted reproduction 
(Shanbhag et al. 2007). An increased dose of gonadotrophin did not improve the outcome of in-
vitro fertilization treatment in several studies (Land et al. 1996; Klinkert et al. 2005; Lekamge et 
al. 2008). Letrozole has been used in ovulation induction and ovarian stimulation (Mitwally and 
Casper 2001; Mitwally and Casper 2004; Badawy et al. 2009a; Badawy et al. 2009b). Mitwally 
and Casper (2002) in an observational study reported that a sequential regimen of letrozole and 
gonadotrophin in intrauterine insemination cycles was associated with a significantly lower 
gonadotrophin dosage but a significantly higher number of mature follicles when compared with 
those of previous failed cycles using gonadotrophin alone. The use of letrozole in poor ovarian 
responders during IVF treatment is summarized in Table 5 but results in terms of pregnancy 
outcomes are not consistent. Goswami et al. (2004), Garcia-Velasco et al. (2005), Ozmen et al. 
(2009) and Davar et al. 2010) reported a comparable pregnancy rate in the letrozole group 
whereas Garcia-Velasco et al. (2005) and Yarali et al. (2009) showed a higher implantation rate.  
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Our data confirmed the results of an early RCT with the significantly lower serum estradiol 
concentration and lower dosage of gonadotrophin usage (Goswami et al. 2004). We failed to 
demonstrate the improved implantation rate following sequential use of letrozole as shown in the 
prospective observational study by Garcia-Velasco et al. (2005), probably due to our small 
sample size. A favourable hormonal environment of the follicular fluid was reported in the same 
study; while our data further elaborated on the hormonal concentrations that letrozole may 
provide to give more favourable clinical outcomes. Although the majority of previous studies 
showed a comparable number of oocytes in the letrozole and control groups, our data showed a 
significantly lower number of oocytes retrieved in the letrozole group. This is in line with the 
result of Davar et al. (2010). Despite a smaller number of oocytes obtained in the letrozole 
group, the live-birth rate was higher, although not statistically significantly, in the letrozole 
group than the control group. The required sample size with adequate power to show a 
statistically significant difference in live birth rate would be 139 patients in each group, in total 
278 women. 
 
All the above trials used 2.5 mg letrozole daily for 5 days, either sequentially or concomitantly. 
A RCT using 7.5 mg letrozole in intrauterine insemination showed a non-significantly higher 
number of follicles than using 100 mg clomiphene citrate in women with unexplained infertility 
(Al-Fozan et al. 2004). There are no studies on the use of 7.5 mg or even higher dosage of 
letrozole in IVF treatment. The optimal dosage or duration of letrozole treatment remains unclear 
and requires further studies to refine it.  
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Another advantage of the letrozole regimen is the lower cost as a result of the lower dose of FSH 
used (Goswami et al. 2004). Based on our data, using letrozole in poor ovarian responders would 
reduce the HMG dosage by 915 IU for each patient on average. This would save 140 US dollars 
(about 25% reduction) in the Hong Kong setting, including the cost required for the purified 
urinary gonadotrophin, letrozole tablets and GnRH antagonist. If using recombinant products 
instead of the urinary products, the cost would drop by 32.2% (1,331 dollars to 902 dollars). In 
view of the comparable live-birth rate, the use of letrozole would be a more favourable protocol 
in poor ovarian responders.  
 
One major concern of using letrozole in ovulation induction or ovarian stimulation is its possible 
teratogenicity (Biljan et al. 2005). Animal data showed embryo and fetal death in both rats and 
rabbits, and congenital malformation of kidneys and ureters, and altered sexual function in male 
offspring in rats (Rockville 2003; Gill et al. 2008). The data from humans seem to be reassuring 
as no congenital abnormality has been linked to the use of letrozole (Tulandi et al. 2006) which 
has a short half-life of 45 hours. There is a sufficient time interval for complete clearance after its 
administration in the early follicular phase, i.e. days 2 - 6 of the cycle in ovulation induction or 
ovarian stimulation, so the drug should not be present during the fertilization and implantation 
periods (Requena et al. 2008). In our study, there were no congenital anomalies noted in the 
letrozole group, while in the control group, one patient had second trimester termination of 
pregnancy for fetal body stalk syndrome after conceiving in the first frozen/thawed embryo 
transfer cycle.  
 
Hormone concentrations 
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Serum E2 concentrations were significantly lower in women receiving letrozole together with 
gonadotrophin during ovarian stimulation in all trials (Goswami et al. 2004; Verpoest et al. 2006; 
Schoolcraft et al. 2008; Ozmen et al. 2009; Yarali et al. 2009; Davar et al., 2010). Our data also 
confirmed this. It has been shown that both the embryo quality and endometrial receptivity 
would be improved in a more physiological hormonal environment following a mild ovarian 
stimulation protocol (Devroey et al. 2004) which may explain the comparable live-birth rate in 
the two groups with the significantly lower number of oocytes in the letrozole group.  
  
The baseline serum FSH concentration was comparable in both groups. Although we used the 
sequential regimen of letrozole and gonadotrophin, i.e. we did not give gonadotrophin during the 
first 5 days of stimulation, the serum FSH concentrations were comparable for the letrozole and 
control groups except on day 8, despite the fact that the control group received gonadotrophin 
from day 3 onwards. It is likely that the suppression of estrogen production by letrozole releases 
the negative feedback mechanism causing a rise in the gonadotrophin concentration. The serum 
FSH concentration rose quickly from day 2 to day 4, then plateauing afterwards, so we suggested 
that it may not be necessary to use gonadotrophin concomitantly with letrozole from day 2 to day 
7, as used in previous studies.   
 
Androgen was shown to be pivotal in folliculogenesis (Weil et al. 1998). Other than its action in 
the early stage of follicular differentiation focusing on the enhancement of FSH-stimulated 
follicular differentiation, a gradual transition to a later stage of folliculogenesis would result in 
an increase of the stimulation of FSH and LH and androgen mainly becomes a substrate for 
estrogen synthesis (Tetsuka and Hillier 1997). Animal studies also revealed that testosterone 
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augmented follicular FSH receptor expression in granulose cells suggesting that androgens 
promoted follicular growth and estrogen biosynthesis indirectly by amplification of the effect of 
FSH (Weil et al. 1999). However, there are scarce data on the effect of letrozole use on the intra-
ovarian environment, except one small prospective study (Garcia-Velasco et al. 2005). As 
letrozole selectively blocks the conversion from androgen to estrogen by suppressing the action 
of aromastase, the androgen concentration in the follicular fluid would be increased. Follicular 
fluid testosterone concentration was reported to be lower in the poor ovarian responders (Bahceci 
et al. 2007), and serum androstenedione in cycles not cancelled was found to be significantly 
higher than that in cancelled cycles in poor ovarian responders (Balasch et al. 2006). Our data 
confirmed follicular fluid androgen concentrations were significantly higher in the letrozole 
group than that in the control group, which was consistent with those of the previous study 
(Garcia-Velasco et al. 2005). 
 
One longitudinal study reported a positive correlation between the follicular fluid AMH 
concentration and pregnancy rate and also with the number of oocytes retrieved (Wunder et al. 
2008). Follicular fluid AMH levels were positively correlated with the FSH sensitivity (Dumesic 
et al. 2009), and the fertilization rate (Takahashi et al. 2008). Our data showed that the follicular 
fluid AMH concentrations were significantly higher after the use of letrozole, which further 
supports the favourable hormonal profiles especially in cases of poor ovarian responders. 
However, the mechanism of the increase in AMH concentrations after letrozole treatment and its 
effect on growing follicles are still unclear.  
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Elevated follicular fluid levels of inhibin B and estradiol have been reported to be related to the 
oocyte retrieval rate, better ovarian response and higher pregnancy rate (Ocal et al. 2004; Wen et 
al. 2006). However, in our study, we failed to demonstrate the difference in estradiol and inhibin 
B level in follicular fluid between the two groups.  
 
Limitation 
One of the limitations of the present study was that we included both poor ovarian responders 
and those with a poor ovarian reserve as shown by a low AFC. The primary outcome was the 
number of oocytes obtained rather than the live-birth rate. The sample size was not large enough 
to show any statistical significance in the live-birth rate. The study was prematurely terminated 
because of recruitment difficulties. The significant difference in the miscarriage rate should be 
interpreted with caution as it could be a chance event.   
 
Conclusion 
Sequential use of letrozole and gonadotrophin in poor responders resulted in a significantly 
lower total dosage and shorter duration of gonadotrophin administration, significantly fewer 
oocytes retrieved but a comparable live-birth rate and a significantly lower miscarriage rate, 
when compared to gonadotrophin alone. Further larger trials are required to confirm the findings. 
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Table	  1.	  Details	  of	  hormone	  assays	  
Laboratory	  tests	   Limit	  of	  
detection	  
Intra-­‐assay	  CV	  
(%)	  
Inter-­‐assay	  CV	  
(%)	  
Manufacturer	  
Estradiol	  (pmol/L)	   73	   4.0	   5.0	   Beckman	  Coulter	  	  
Progesterone	  (nmol/L)	   0.25	   4.4	   3.6	   Beckman	  Coulter	  
FSH	  (IU/L)	   0.2	   3.1	   5.4	   Beckman	  Coulter	  
LH	  (IU/L)	   0.2	   3.6	   4.3	   Beckman	  Coulter	  
Testosterone	  (ng/mL)	   0.04	   4.8-­‐6.8	   2.8-­‐4.9	   Immunoassay	  
(DSL)	  
Androstenedione	  
(ng/mL)	  
0.03	   7.8-­‐10.3	   6.3-­‐9.2	   DSL	  
AMH	  (pM)	   1	   0-­‐11.4	   0-­‐14	   Immunotect	  (BC)	  
Inhibin	  B	  (pg/mL)	   7	   3.5-­‐5.6	   6.2-­‐7.6	   DSL	  
	  
CV-­‐coefficients	  of	  variation.	  	  FSH	  -­‐	  follicle-­‐stimulating	  hormone.	  LH	  –	  luteinizing	  hormone.	  AMH	  
–	  antimullerian	  hormone.	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Table	  2.	  Demographic	  data.	  
	  
	   Letrozole	  group	  
(n=26)	  
Control	  group	  
(n=27)	  
Age	  (yrs)	   37.3	  ±	  2.4	   36.2	  ±	  2.2	  
Duration	  of	  subfertility	  (yrs)	   5.3	  ±	  2.5	   4.7	  ±	  2.0	  
Body	  mass	  index	  (kg/m2)	   21.0	  ±	  2.3	   20.7	  ±	  2.1	  
Primary	  subfertility	  (%)1	   18	  (69.2)	   22	  (81.5)	  
Cause	  of	  subfertility	   	   	  
-­‐	  tubal	   6	  (23.0)	   4	  (14.8)	  
-­‐	  endometriosis	   3	  (11.5)	   8	  (29.6)	  
-­‐	  male	   10	  (38.5)	   11	  (40.7)	  
-­‐	  unexplained	   3	  (11.5)	   2	  (7.4)	  
-­‐	  mixed	   4	  (15.4)	   2	  (7.4)	  
Smoking	  status	   1	  (3.8)	   1	  (3.7)	  
	  
Data	  presented	  as	  mean	  ±	  standard	  deviation	  or	  number	  (percentage).	  
There	  were	  no	  statistically	  significant	  differences	  between	  the	  two	  groups.	  
 
Table	  3.	  Comparison	  of	  outcomes.	  
	  
	   Letrozole	  group	  
(n=26)	  
Control	  group	  
(n=27)	  
p-­‐value	  
Dosage	  of	  gonadotrophins	  (IU)	   1507.5	  ±	  570.0	   2422.5	  ±	  435.0	   <0.001	  
Duration	  of	  stimulation	  (days)	   6.4	  ±	  2.5	   10.2	  ±	  2.6	   <0.001	  
Antagonist	  dosage	  (IU)	   4.7	  ±	  1.8	   4.9	  ±	  2.1	   NS	  
Total	  no	  of	  follicle	  aspirateda	   3.0	  (0-­‐11)	   5.0	  (0-­‐26)	   0.001	  
No	  of	  oocytes	  retrieveda	   2.0	  (0-­‐4)	   4.0	  (0-­‐19)	   0.001	  
No	  of	  embryos	  cleaveda	   1.0	  (0-­‐3)	   2.0	  (0-­‐15)	   0.020	  
No	  of	  embryos	  transferreda	   1.0	  (0-­‐2)	   2.0	  (0-­‐3)	   NS	  
Cancellation	  rate	  (due	  to	  
premature	  luteinisation)b	  
4	  (15.0%)	   2	  (7.4%)	   NS	  
Cancellation	  rate	  (all	  causes)b	   6	  (23.1%)	   4	  (14.8%)	   NS	  
Implantation	  rateb	   5/23	  (21.7%)	   5/36	  (13.9%)	   NS	  
Ongoing	  pregnancy	  rateb	   5	  (19.2%)	   2	  (7.4%)	   NS	  
Live	  birth	  rateb	   5	  (19.2%)	   2	  (7.4%)	   NS	  
Miscarriage	  rateb	   0	  (0)	   3/5	  (60.0%)	   0.038	  
	  
Data	  were	  presented	  as	  mean	  ±	  standard	  deviation	  
aData	  were	  given	  as	  median	  (range)	  
bData	  presented	  as	  number	  (percentage).	  
NS	  =	  not	  statistically	  significant.	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Table	  4.	  Follicular	  fluid	  hormone	  concentrations.	  
	  
	   Letrozole	  group	  
	  (n=18)	  
Control	  group	  
(n=18)	   p-­‐value	  
Estradiol	  (pmol/L)	   1186510	  (330010-­‐2484680)	   1012030	  (518-­‐4799080)	   NS	  
Progesterone	  (nmol/L)	   45313	  (9442-­‐62351)	   45230	  (38-­‐58016)	   NS	  
FSH	  (IU/L)	   11.4	  (6.0-­‐16.2)	   9.0	  (5.3-­‐121.5)	   0.046	  
LH	  (IU/L)	   1.0	  (0.1-­‐4.6)	   0.4	  (0.1-­‐6.4)	   NS	  
Testosterone	  (ng/mL)	   19.2	  (9.4-­‐53.0)	   9.0	  (2.1-­‐52.4)	   0.009	  
Androstenedione	  (ng/mL)	   10.8	  (3.5-­‐234.1)	   5.0	  (2.4-­‐370.1)	   0.001	  
AMH	  (pM)	   3.0	  (1.2-­‐45.8)	   1.9	  (0.8-­‐5.1)	   0.034	  
Inhibin	  B	  (pg/mL)	   390.3	  (31.3-­‐2568.3)	   321.4	  (0-­‐1114.6)	   NS	  
	  
Data	  presented	  as	  median	  (range).	  
AMH-­‐anti-­‐Müllerian	  hormone,	  NS	  =	  not	  statistically	  significant.	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Table	  5.	  Summary	  of	  studies	  using	  letrozole	  in	  poor	  ovarian	  responders	  during	  in-­‐vitro	  
fertilisation	  treatment.	  
	  
	   No	  of	  
women	  
Days	  of	  
FSH	  
FSH	  
dosage	  
(IU)	  
ET	  (mm)	   E2	  
(pg/ml)	  
No	  of	  
eggs	  
IR	  (%)	   PR	  
(%)	  
GnRHa	  long	  protocol	  
Goswami	  et	  al.,	  2004	  (RCT)	   	   	   	   	   	   	   	  
Let+rFSH	   13	   -­‐	   150	  (0)a	   8.5	  (0.4)	   227	  (45)a	   1.6	  
(0.8)	  
-­‐	   23	  
rFSH	   25	   -­‐	   2865	  
(228)a	  
7.4	  (0.4)	   380	  (46)a	   2.1	  
(0.7)	  
-­‐	   24	  
Antagonist	  protocol	  
Garcia-­‐Velasco	  et	  al.,	  2005	  (Prospective	  Observational)	   	   	   	   	  
Let+rFSH	   71	   9.3	  (0.3)	   3627	  
(116)	  
9.6	  (0.5)	   770	  (67)	   6.1	  
(0.4)a	  
25a	   22.4	  
rFSH	   76	   8.9	  (0.2)	   3804	  
(127)	  
9.8	  (0.3)	   813	  (60)	   4.3	  
(0.3)a	  
9.4a	   15.2	  
Verpoest	  et	  al.,	  2006	  (RCT)	   	   	   	   	   	   	   	  
Let+rFSH	   10	   -­‐	   -­‐	   10.3a	   -­‐	   13.8	  
(9.2)	  
31.3	   50	  
rFSH	   10	   -­‐	   -­‐	   8.1a	   -­‐	   9.6	  
(7.7)	  
12.5	   20	  
Ozmen	  et	  al.,	  2009	  (RCT)	   	   	   	   	   	   	   (/ET)	  
Let+rFSH	   35	   -­‐	   2980	  
(435)a	  
9.3	  (2.6)	   1870	  
(159)a	  
4.9	  
(1.6)	  
-­‐	   25.8	  	  
rFSH	   35	   -­‐	   3850	  
(580)a	  
9.7	  (3.2)	   2015	  
(175)a	  
4.8	  
(1.4)	  
-­‐	   20	  
Microflare	  protocol	  
Schoolcraft	  et	  al.,	  2008	  (Prospective)	   	   	   	   	   	   	  
Let+rFSH	   179	   9.9	  (1.3)	   4223	  
(743)	  
-­‐	   1403	  
(965)a	  
12	  (6)	   15	   37a	  
GnRHa	  
+rFSH	  
355	   10.1	  (1.6)	   3938	  
(975)	  
-­‐	   3147	  
(1189)a	  
13	  
(5.3)	  
21	   52a	  
Yarali	  et	  al.,	  2009	  (Retrospective)	   	   	   	   	   	   (/ET)	  
Let+rFSH	   212	   9.0	  	  
(2.5)a	  
4020	  
(1178)a	  
9.7	  (2.4)	   794	  
(711)a	  
4.1	  
(3.4)a	  
14.5a	   22.8	  
GnRHa	  
+rFSH	  
673	   10.2	  (4.0)a	   4538	  
(1493)a	  
10.1	  
(2.5)	  
1805	  
(1228)a	  
6.7	  
(4.5)a	  
9.8a	   17.4	  
Davar	  et	  al.,	  2010	  (RCT)	   	   	   	   	   	   	   	  
Let+FSH	   45	   8.5	  (1.1)a	   3158	  
(563)a	  
8.3	  (1.3)	   477	  (54)a	   2.8	  
(2.7)a	  
3.8	   5.3	  
GnRHa	  +FSH	   49	   9.2	  (1.2)a	   3458	  
(533)a	  
8.4	  (1.2)	   1065	  
(706)a	  
4.4	  
(2.7)a	  
7.7	   14.3	  
ET	  –	  endometrial	  thickness.	  E2	  –	  estradiol.	  IR	  –	  implantation	  rate.	  PR	  –	  pregnancy	  rate.	  (/ET)	  –	  
pregnancy	  rate	  per	  embryo	  transfer.	  Let	  –	  letrozole.	  	  
ap<0.05	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Legends 
Figure 1 Flow diagram of patient participation in the trial. 
Figure 2. Serum hormone concentrations on various days of ovarian stimulation. Panel 2a,  
oestradiol concentrations of the letrozole group were significantly lower than the control group 
from day 4 to the day of hCG (all p-values < 0.001). Panel 2b, FSH concentrations of the 
letrozole and control groups were comparable on most the days, except on day 8 when FSH 
concentration of the letrozole group was significantly lower than that of the control group (p 
<0.001). Panel 2c, LH concentrations of the letrozole group were significantly higher than the 
control groups on days  4, 6 and 8 (p 0.018, <0.001 and 0.018 respectively). 
